EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Feasibility and Outcomes of Concomitant Boost in Prone Hypofractionated Whole-Breast Irradiation Using 3D-Conformal Radiotherapy

Pavnesh Kumar, Tanun Jitwatcharakomol, Jonathan E Schoenhals, Sierra J Daniel, Mariella Mestres-Villanueva, Yevgeniya Gokun, Thamilini Pathmarajah, Therese Y Andraos, Rebekah Young, Jacob M Eckstein, Julia R White, Jose G Bazan und 3 weitere

Clinical Breast Cancer · 2026-11 · 26 (11) · 66-73

DOI: 10.1016/j.clbc.2026.09.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026-11. Verfasst von Pavnesh Kumar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH. Hauptthemen laut MEDLINE: Breast Neoplasms, Radiotherapy, Conformal, Neoplasm Recurrence, Local, Carcinoma, Intraductal, Noninfiltrating. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Adjuvant radiation after breast-conserving surgery (BCS) reduces recurrence and improves survival in early breast cancer. While hypofractionated whole-breast irradiation (WBI) is standard, use of a concomitant boost (CB) remains limited. We report outcomes using moderately hypofractionated WBI with CB (HFRT-CB) delivered in the prone position with 3D conformal radiation therapy (3D-CRT). MATERIALS AND METHODS: Following institutional review board approval, records of patients with early-stage, node-negative invasive breast cancer, or ductal carcinoma in situ treated with BCS and HFRT-CB in prone position were retrospectively reviewed. The whole breast received 40 Gy with a CB 48 Gy to the lumpectomy cavity, delivered in 15 fractions. Outcomes included ipsilateral breast tumor recurrence (IBTR), disease-free survival (DFS), local recurrence-free survival (LRFS), and overall survival (OS). Toxicities were graded using CTCAE v4.0, and physician-reported cosmesis using the Harvard Cosmetic Scale. RESULTS: A total of 393 patients, with a median age of 60, were treated prone between February 2013 and March 2025. Median follow-up was 39 months. At 3 and 5 years, DFS was 98.5% and 97.6%, and LRFS was 99.6% and 98.8%, respectively. IBTR rates were 0.4% and 1.2%. OS was 97.7% and 94.6%, with a 5-year breast cancer-specific survival of 98.8%. One patient (0.3%) had grade 3 acute toxicity; no grade ≥ 3 late toxicities occurred. Good/excellent cosmesis was reported in 96.2% at 1 year and 88.5% at 3 years. CONCLUSION: Prone HFRT-CB with 3D-CRT offers excellent tumor control, minimal toxicity, and favorable cosmesis, supporting its use as a safe and efficient adjuvant option after BCS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsRadiotherapy, ConformalNeoplasm Recurrence, LocalCarcinoma, Intraductal, NoninfiltratingCarcinoma, Ductal, BreastHumansFemaleMiddle AgedRetrospective StudiesAgedFeasibility StudiesMastectomy, SegmentalRadiation Dose HypofractionationProne PositionRadiotherapy, AdjuvantAdultFollow-Up StudiesAged, 80 and overDisease-Free SurvivalTreatment Outcome

Stichwörter der Autor:innen

Breast-conserving surgeryCosmetic outcomesEarly-stage breast cancerLocal tumor controlRadiation

Autor:innen und Institutionen

  • Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH.
  • Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH; Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok…
  • Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, OH.
  • The Ohio State University College of Medicine, Columbus, OH.
  • Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS.
  • Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA.

Zitieren

APA

Kumar, P., Jitwatcharakomol, T., Schoenhals, J. E., Daniel, S. J., Mestres-Villanueva, M., Gokun, Y., Pathmarajah, T., Andraos, T. Y., Young, R., Eckstein, J. M., White, J. R., Bazan, J. G., Healy, E., Jhawar, S. R., & Beyer, S. J. (2026). Feasibility and Outcomes of Concomitant Boost in Prone Hypofractionated Whole-Breast Irradiation Using 3D-Conformal Radiotherapy. Clinical Breast Cancer, 26(11), 66-73. https://doi.org/10.1016/j.clbc.2026.09.012

Vancouver

Kumar P, Jitwatcharakomol T, Schoenhals JE, Daniel SJ, Mestres-Villanueva M, Gokun Y, et al. Feasibility and Outcomes of Concomitant Boost in Prone Hypofractionated Whole-Breast Irradiation Using 3D-Conformal Radiotherapy. Clinical Breast Cancer. 2026;26(11):66-73. doi:10.1016/j.clbc.2026.09.012

BibTeX
@article{Kumar2026,
  author = {Kumar, Pavnesh and Jitwatcharakomol, Tanun and Schoenhals, Jonathan E and Daniel, Sierra J and Mestres-Villanueva, Mariella and Gokun, Yevgeniya and Pathmarajah, Thamilini and Andraos, Therese Y and Young, Rebekah and Eckstein, Jacob M and White, Julia R and Bazan, Jose G and Healy, Erin and Jhawar, Sachin R and Beyer, Sasha J},
  title = {Feasibility and Outcomes of Concomitant Boost in Prone Hypofractionated Whole-Breast Irradiation Using 3D-Conformal Radiotherapy},
  journal = {Clinical Breast Cancer},
  year = {2026},
  volume = {26},
  number = {11},
  pages = {66--73},
  doi = {10.1016/j.clbc.2026.09.012}
}
Kostenlos starten →